Insulin Aspart Injection Shortage
Last Updated: May 20, 2024
Status: Current
Products Affected - Description
-
- Fiasp Flextouch subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3204-15
Reason for the Shortage
-
- Novo Nordisk states the shortage is due to increased demand. The company did not provide availability information on Relion products.
Available Products
-
- Fiasp subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 00169-3201-11
- Fiasp Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3205-15
- Insulin Aspart Flexpen subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 73070-0103-15
- Insulin Aspart Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 73070-0102-15
- Novolog subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 00169-7501-11
- Novolog Flexpen subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-6339-10
- Novolog Penfill subcutaneous injection, Novo Nordisk, 100 units/mL, 3 mL pen, 5 count, NDC 00169-3303-12
- Insulin Aspart subcutaneous injection, Novo Nordisk, 100 units/mL, 10 mL multiple dose vial, 1 count, NDC 73070-0100-11
Estimated Resupply Dates
-
- Novo Nordisk has Fiasp Flextouch 3 mL pens on back order and the company estimates a release date in July 2024.
Updated
Updated May 20, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 10, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.